The anticancer effect of the TLR4 inhibition using TAK‐242 (resatorvid) either as a single agent or in combination with chemotherapy: A novel therapeutic potential for breast cancer

Increasing pieces of evidence indicate that inflammatory processes facilitate tumorigenesis; tumor cells simulate the mechanisms by which innate immune cells produce pro‐inflammatory cytokines to exploit them for their own survival and proliferation. Toll‐like receptor 4 (TLR4), which serves as one of the most well‐known receptors on the surface of the immune cells, is often expressed ectopically in the tumor cells resulting in tumor progression, invasion, and chemoresistance. In this study, we examined the anticancer effects of TAK‐242, a small molecule inhibitor of TLR4, on different breast cancer cell lines: MCF7, SKBR3, MDA‐MB‐231, and BT‐474. Our results showed that the TLR4 inhibition, as revealed by the downregulation of TLR4 downstream genes, exerted desirable cytotoxicity on the TLR4‐expressing cells, at least partly, through the downregulation of EGFR and c‐Myc genes. TAK‐242 also inhibited the proliferation of anoikis‐resistant cells and suppressed the clonal growth of the indicated cells. The results of this study propose a mechanistic pathway by which the inhibition of TLR4 using TAK‐242 could augment apoptotic cell death through the alteration of both nuclear factor‐кB‐ and p53‐related apoptosis genes in breast cancer cells, especially cells with overexpression of TLR4. Taken together, this study supports the idea that the activation of inflammatory pathways may have a crucial role in breast cancer progression and the inhibition of TLR4 using TAK‐242, either as a single agent or in combination, seems to be a novel promising strategy that could be clinically available in foreseeable future. In this study, we found that the inhibition of toll‐like receptor 4 using TAK‐242 results in the inhibition of proliferation and induction of apoptosis in the toll‐like receptor 4 (TLR4)‐expressing breast cancer cell lines.